Zurich Cantonal Bank
ALNY icon

Zurich Cantonal Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Zurich Cantonal Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-89,804
Closed -$35.7M – 2587
2025
Q4 		$35.7M Buy
+89,804
New +$39.7M 0.08% 206

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zurich Cantonal Bank's ALNY Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 74,920 shares worth $24.8M. The stake represents 0.05% of the portfolio and ranks #283 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in ALNY as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in ALNY in Q3 2013 and has held it in 48 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Zurich Cantonal Bank held 74,920 shares of Alnylam Pharmaceuticals worth $24.8M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Zurich Cantonal Bank's portfolio in Q1 2026, its #283 holding.
  • Zurich Cantonal Bank first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 48 quarters since.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.